Citi keeps this biotech stock a top pick after trial clears key efficacy milestone

August 18, 2026 3:00 AM

Citi Research reiterated its "buy," Top Pick rating and $1,203 price target on this biopharmaceutical company after the Belgian biotech's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found